• Aaron Neinstein

Two clinical trials ongoing with diabetes mhealth

There are two ongoing clinical trials to be aware of.

One is at the Univ of Maryland and is using the forementioned Telcare meter.  This study is a 6-month pilot study taking 100 patients with diabetes (both types 1 and 2) and randomizing them to either typical glucose meter or the Telcare meter.  The outcome measures will be to see if connecting the patients via the Telcare meter will improve self-monitoring of blood glucose (SMBG) compliance, to see if A1c is affected, and to see if patient satisfaction is improved.

The other is being sponsored by a company called Diabetech with a link to the trial information here.  This study is using an investigational device designed by Diabetech that attaches a self-contained wireless accessory to a glucose meter, and then transmits data to a centralized data management system.  The system then analyzes the data and either sends educational materials to the patient or alerts or reports to the healthcare team.  The primary outcome measures in this study are glucose control and patient satisfaction.  The secondary outcome measures are HbA1c, self-test frequency of glucoses, and standard deviation of HbA1c and SMBG.

#diabetes #diabetech #telcare #wireless #mhealth #Glucosemeter #clinicaltrials #IPhone #Clinicaltrial

0 views0 comments
  • Twitter
  • LinkedIn
  • Instagram

Dr. Aaron Neinstein is Associate Professor in the UCSF Division of Endocrinology and Director of Clinical Informatics at the UCSF Center for Digital Health Innovation, with a clinical practice focused on diabetes care. He is considered an expert in diabetes technology, including the use of insulin pumps and continuous glucose monitors, as a nationally-invited speaker and invited author to outlets like CNBC and Medscape, peer-reviewed author, and advisor to numerous companies.

© 2020 by Aaron Neinstein MD